Alnylam opens new European office in UK, aimed at expanding global footprint

20 September 2016

US RNAi therapeutics company Alnylam Pharmaceuticals (Nasdaq: ALNY) is expanding its global footprint with the opening of a new development and commercial hub in Maidenhead, UK, with a multi-million pound investment, seemingly undeterred by Britain’s referendum decision to leave the European Union.

In anticipation of substantial growth across Alnylam over the next five years, the office opens with a core clinical development, regulatory affairs and commercial team and space for an additional 100 employees.

"Since our inception in 2002, Alnylam has pioneered new and innovative potential treatments for challenging diseases. This effort has yielded a robust clinical pipeline with 10 programs in development across our three Strategic Therapeutic Areas or STArs," said Akshay Vaishnaw, executive vice president of R&D and chief medical officer at Alnylam.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK